Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HAT1 | O14929 | 2/20 | 0.51 |
| ▸ | EP300 | Q09472 | 2/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870755 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| SCHEMBL3173912 | 0.86 | KMT2A (0.76) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| SCHEMBL31588275 | 0.86 | KMT2A (0.76) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| SCHEMBL5738787 | 0.83 | KMT2A (0.71) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| SCHEMBL5738792 | 0.83 | KMT2A (0.71) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| SCHEMBL5162767 | 0.82 | KMT2A (0.69) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| Hydrochloric Acid SCHEMBL7248228 | 0.82 | KMT2A (0.69) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| SCHEMBL25421155 | 0.81 | KMT2A (0.68) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| SCHEMBL22167164 | 0.81 | KMT2A (0.68) | KMT2AALDH1A1MEN1PBRM1GPR84 | |
| SCHEMBL14496307 | 0.81 | KMT2A (1.00) | KMT2AALDH1A1MEN1PBRM1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368034-A1 | THIOTRIAZOLE COMPOUND AND ITS USE IN PARASITIC PROTOZOAL INFECTIONS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-28 | — | — | US | disclosed |
| US-20170368034-A1 | THIOTRIAZOLE COMPOUND AND ITS USE IN PARASITIC PROTOZOAL INFECTIONS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-28 | — | — | US | disclosed |
| EP-3237400-A1 | THIOTRIAZOLE COMPOUND AND ITS USE IN PARASITIC PROTOZOAL INFECTIONS | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102431-A1 | THIOTRIAZOLE COMPOUND AND ITS USE IN PARASITIC PROTOZOAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016102431-A1 | THIOTRIAZOLE COMPOUND AND ITS USE IN PARASITIC PROTOZOAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368034-A1 | THIOTRIAZOLE COMPOUND AND ITS USE IN PARASITIC PROTOZOAL INFECTIONS | TPMT, TUBA3C, MAPT | KMT2A 1085/4885ALDH1A1 636/4885MEN1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.